Fate Therapeutics, Inc. (FATE)
NasdaqGM · USD · Healthcare · Biotechnology
$2.06 (-2.61%) as of
Key statistics
- Market cap
- 246.23M
- Forward P/E
- -2.12
- EPS (TTM)
- -1.0500
- Dividend yield
- 0.00%
- 52-week range
- 0.9500 – 3.2300
- Beta
- 2.53
- Revenue (TTM)
- 6.49M
- Profit margin
- 0.00%
- Analyst target
- $5.74
- Volume
- 1.46M
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA, United States
- Employees
- 161
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.